Gaudium IVF Q4FY26 Revenue Surges 12.7% YoY to ₹30.35 Cr; PAT Jumps 29.5%
Gaudium IVF reported Q4FY26 revenue of ₹30.35 Cr, up 12.7% YoY. FY26 revenue grew 47.6% to ₹104.35 Cr. Q4FY26 PAT rose 29.5% to ₹8.36 Cr, and FY26 PAT increased 27.7% to ₹24.48 Cr. The company adopted AI-led embryology in April 2026. It plans to open 10 new IVF hubs in FY27.
The announcement details significant financial performance improvements and strategic initiatives like AI integration and expansion plans which are likely to have a substantial impact on the company's future growth and market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT for both the quarter and the full fiscal year, along with strategic technological advancements and expansion plans.
Gaudium IVF and Women Health Limited announced its Audited Financial Results for the quarter and financial year ended March 31, 2026. The company reported a consolidated revenue from operations of ₹30.35 Crore for Q4FY26, a 12.74% increase year-on-year (YoY) from ₹26.92 Crore in Q4FY25. For the full fiscal year FY26, revenue reached ₹104.35 Crore, up 47.56% YoY from ₹70.72 Crore in FY25.
EBITDA for Q4FY26 was ₹12.17 Crore, a 39.56% increase YoY, with an EBITDA margin of 40.10%. For FY26, EBITDA stood at ₹37.70 Crore, a 31.69% increase YoY, and the EBITDA margin was 36.13%. Profit After Tax (PAT) for Q4FY26 grew by 29.46% YoY to ₹8.36 Crore, with a PAT margin of 27.54%. For FY26, PAT increased by 27.69% YoY to ₹24.48 Crore, with a PAT margin of 23.47%.
In a significant technological advancement, Gaudium IVF integrated AI-led embryology into its clinical practice in April 2026 through a partnership with UK-based IVF 2.0, deploying SiD and ERICA platforms. The company maintained its network of 7 hubs and 28 spokes, achieving a clinical pregnancy success rate of 58% on the first IVF attempt. Looking ahead, Gaudium IVF plans to operationalize 3 new IVF hubs soon, with a total of 10 planned for FY27 and 8 for FY28, expanding its reach into Tier-II markets and reinforcing existing hubs.
What to do with a filing like this
Gaudium IVF and Women Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gaudium IVF and Women Health Limited. Read the original for the full detail.